CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China
- Written by PR Newswire
![]() |
SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, and Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (Huadong Medicine; SZ: 000963), today...















